Nifedipine is a calcium channel blocker medication which is used for treating high blood pressure and chest pain caused by angina. Calcium channel blockers work by relaxing muscles in artery walls and increasing the supply of blood and oxygen to the heart. Nifedipine was first approved for medical use in 1983. It works by blocking calcium channels in heart and artery muscle cells. This helps blood vessels dilate, thus lowering blood pressure and reducing strain on the heart. It comes in both short-acting and long-acting tablet formulations and has proven effective for millions worldwide in controlling blood pressure and reducing chest pain.
Market Dynamics:
A growing number of people suffering from hypertension and cardiovascular illnesses and increasing aging population are major factors expected to drive growth of the global nifedipine medication market during the forecast period.
Moreover, market players are indulged in launching new products for nifedipine and this is expected to increase the growth of the global nifedipine market, over the forecast period. For instance, on September 18, 2019, AVET Pharmaceuticals, a developer of generic medicines, launched nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia and adds to Avet’s robust portfolio of generic oral solid products.
However, patent expiration, regulatory challenges, adverse effects, availability of alternative treatments, shifting treatment paradigms, pricing pressures are expected to hamper the growth of the global nifedipine medication market over the forecast period.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook